XP Health, a benefit platform development company for digital vision, has raised $17.1 million in a Series A funding round led by HC9 Ventures, Valor Capital Group and ManchesterStory.
Additional investors include Core Innovation Capital, GSR Ventures, Canvas Ventures, Plug and Play, CameronVC, Ken Goulet, Kevin Hill, Jeff Epstein and Brett Rochkind. This recent funding round follows a $5.5 million raise in 2021.
“This funding round allows us to enhance the functionality of the platform and deliver an outstanding consumer experience in the most affordable way for employers, insurers, and employees,” said Antonio Moraes, co-founder. founder and CEO of XP Health, said in a statement.
“We provide a game changer in how people access and experience employee benefits – with the ultimate goal of positively impacting the lives of hundreds of millions of people through benefits. high-quality, accessible and affordable health.”
Lung health firm Optellum has announced the close of a $14 million Series A funding round led by British venture capital firm Mercia with participation from US firms Intuitive Ventures and Black Opal.
Its Virtual Nodule Clinic software is used to monitor, evaluate, and characterize lung nodules. The company has achieved FDA License in the United States, CE-MDR in the European Union and UKCA in the United Kingdom for the platform. A CE marking certificate (CE-MDR) is required for the commercialization of medical devices in the EU. The UK Conformity Assessment mark indicates that a product conforms to applicable requirements to be sold in the UK.
“[Virtual Nodule Clinic] can help doctors identify and monitor at-risk patients and optimally diagnose early signs of lung cancer – so treatment can be started earlier for patients with tumors and to minimize invasive procedures such as biopsies on benign lesions,” the company said in a press release.
The company behind Cionic Neural Sleeve has received $12.5 million in Series A funding led by BlueRun Ventures, with participation from EPIC Ventures, LDV Capital, Caffeinated Capital, and JobsOhio Growth Capital Fund.
This funding round follows Cionic Neural Sleeve’s FDA license in early 2022. Foot wearables provide electrical stimulation so people with calloused feet and muscle weakness can walk more easily. To date, Cionic has received $23 million to build its platform focused on human mobility.
The new round of funding will help the company expand production and supply of mobile technology, and accelerate research trials and commercialization of its products for new indications.
“Future investors realized we needed to act today, and we’re proud to be supported by a group of investors who recognized the need for better solutions and joined Join us on our mission to redefine human mobility.” Cionic Founder and CEO Jeremiah Robison said in a statement.
Kaleidoscope, a cloud-based research platform that maps the data usage of R&D teams, has consolidated a $6 million seed funding round.
It is co-led by Hummingbird Ventures and Dimension, with participation from SV Angel, Hawktail, Caffeinated Capital and individual investors.
The grant will help the company further develop the platform’s product and expand its team, especially with software engineers.
“The way people work in research is changing. Kaleidoscope bridges the gap between teams on a platform that integrates with other software tools. The funding will allow us to deliver the product. and the best user experience to make research more collaborative, reproducible and scalable,” Bogdan Knezevic, CEO and co-founder of Kaleidoscope, said in a statement. .
Arcascope, a health technology company focused on circadian rhythm disruption, announced it has closed a $2.85 million seed round.
The round was led by Supermoon Capital, with participation from New Dominion Angels, Inflect Health, Inception Health, Accelerate Blue Fund, Monroe Brown Seed Fund, AIoT Health, HealthX Ventures and other angel investors.
The company is launching a circadian rhythm management platform, now accessible via a smartphone app, Shift, to address the sleep needs of shift workers.
Surge, a company that develops machine learning technology to decode a patient’s blood samples to predict the risk of complications after surgery, announced a $2.6 million round of funding co-led by AHCC and Boutique Venture Partners. director, starring Nicolas Godin.
The company also received an exclusive license for its patented postoperative complication prediction technology from Stanford University, which includes more than 10 years of research into surgical risk prediction. Surge also signed a research agreement with Stanford with the intention of developing biotechnology innovations.
This new round of funding will help the company grow its team further and conduct clinical studies with more hospitals.
